CDC Allows Novavax Monovalent COVID-19 Boosters for Adults Ages 18 and Older
For Immediate Release: Wednesday, October 19, 2022
Contact: Media Relations
Today, CDC’s Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo allowing Novavax monovalent COVID-19 boosters for adults.
This action gives people ages 18 years and older the option to receive a Novavax monovalent booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed primary series vaccination but have not previously received a COVID-19 booster—and if they cannot or will not receive mRNA vaccines.
Some may be unable to receive an mRNA vaccine as a result of an allergy to a component of an mRNA COVID-19 vaccine, or as a result of a history of a severe allergic reaction (such as anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine, or a lack of availability of an mRNA vaccine. People ages 18 and older may also choose to receive a Novavax monovalent booster if they are unwilling to receive mRNA vaccines, and would otherwise not receive a booster dose.
FDA’s authorization of monovalent COVID-19 boosters and CDC’s recommendation for use, are important steps forward in our country’s comprehensive vaccination program—a program that has helped provide increased protection for all Americans against COVID-19 disease and death.
CDC works 24/7 protecting America’s health, safety and security. Whether disease start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America’s most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.